Chronic hepatitis C virus (HCV) infection is a major public health challenge for Australia, affecting approximately 230,000 people who are at risk of progressive liver fibrosis leading to cirrhosis, liver failure and hepatocellular carcinoma (HCC). The burden of liver disease due to HCV is projected to triple by 2030. The introduction of direct-acting antiviral (DAA) therapies for HCV that are highly effective and well tolerated is a major medical advance. All Australians living with HCV should now be considered for antiviral therapy.
The Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2017 [PDF] was prepared by an expert panel representing the Gastroenterological Society of Australia (Australian Liver Association), the Australasian Society for Infectious Diseases, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, the Australasian Hepatology Association, Hepatitis Australia and the Royal Australian College of General Practitioners.
It provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment.
The resource is available in the below formats: